Should You Buy Moderna Before May 12?
(NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried about future growth since the vaccine is the biotech's only commercialized product.
But things may be about to turn around for Moderna. The biotech company aims to bring as many as 15 new products to market over the next five years and has the late-stage pipeline to support such aspirations. The commercialization of Moderna's next product may be right around the corner if all goes well during the regulatory review stage.
The U.S. Food and Drug Administration (FDA) is set to issue a decision on the company's respiratory syncytial virus (RSV) vaccine candidate by May 12. Should you buy shares of this ambitious biotech company before then?
Source Fool.com
Moderna Inc. Aktie
Überwältigendes Buy-Interesse bei Moderna Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Das durchschnittliche Kursziel der Community für Moderna Inc. liegt bei 120 €, was eine mehr als doppelte Steigerung zum aktuellen Kurs von 58.18 € darstellt.
